skip to content
Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation Preview this item
ClosePreview this item
Checking...

Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation

Author: George A Wells; Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, April 9, 2012.
Series: CADTH therapeutic review.
Edition/Format:   eBook : Document : National government publication : English
Database:WorldCat
Summary:
Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated with substantial morbidity. AF-related mortality is mainly attributable to complications of stroke. Stroke risk can be quantified using a validated tool such as the CHADS2 score. Warfarin, a vitamin K antagonist, is the standard of care for patients with AF and has demonstrated efficacy in the prevention of stroke. Warfarin has a  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: George A Wells; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 867074010
Notes: Title from PDF title page.
Accompanied with: Anticoagulation monitoring and reversal strategies for Dabigatran, Rivaroxaban, and Apixaban : a review of clinical effectiveness / prepared by Canadian Agency for Drugs and Technologies in Health.
Description: 1 online resource (1 PDF file (v, 173, ii, 13 pages)) : illustrations.
Contents: 1. Executive summary: 1.1. Background; 1.2. Primary research questions; 1.3. Methods; 1.4. Results; 1.5. Strengths of review; 1.6. Limitations of review; 1.7. Conclusions --
2. Introduction: 2.1. Background --
atrial fibrillation and anticoagulants; 2.2. Impact of the condition on the health of the population; 2.3. Interventions currently available; 2.4. New proposed treatments; 2.5. Possible benefits and safety of the old and new drugs; 2.6. Economic context --
3. Clinical review: 3.1. Primary research questions; 3.2. Methods; 3.3. Systematic review results; 3.4. Individual study results; 3.5. Network meta-analysis results --
4. Economic review: 4.1. Primary research questions; 4.2. Methods; 4.3. Results: sensitivity analysis; 4.4. Analysis of variability; 4.5. Analysis of the effect of changes in the duration of treatment effect --
5. Discussion: 5.1. Summary of available evidence; 5.2. Interpretation of results; 5.3. Knowledge gaps; 5.4. Strengths and limitations --
6. Conclusions --
7. Appendices --
8. References.
Series Title: CADTH therapeutic review.
Other Titles: New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation
Responsibility: authors, George Wells [and 9 others].
More information:

Abstract:

Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated with substantial morbidity. AF-related mortality is mainly attributable to complications of stroke. Stroke risk can be quantified using a validated tool such as the CHADS2 score. Warfarin, a vitamin K antagonist, is the standard of care for patients with AF and has demonstrated efficacy in the prevention of stroke. Warfarin has a narrow therapeutic window, produces varied responses among patients, and interacts with some types of food and other drugs, all of which necessitates routine laboratory monitoring. Improved understanding of the blood clotting cascade has led to the development of several new oral anticoagulants (NOACs) that offer a more targeted mechanism of anticoagulation. These NOACs include the direct thrombin inhibitor, dabigatran, and the direct factor Xa inhibitors, rivaroxaban and apixaban, which have either been approved (dabigatran and rivaroxaban) for use or are currently under regulatory review (apixaban) for the prevention of stroke and systemic embolism (SE) in patients with AF. Although NOACs have demonstrated efficacy within clinical trials in preventing stroke and SE in patients with AF, the relative effectiveness and cost-effectiveness in clinical practice of these agents is not clear. In addition, the relative effectiveness and cost-effectiveness of the NOACs and warfarin within specific subpopulations of AF patients is not clear. Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. Are there sub-populations of AF patients that would benefit more from using NOACs compared to warfarin?2. Are there sub-populations of AF patients that would benefit more from one of the NOACs versus another? At the time of this report, apixaban was not approved by Health Canada for the prevention of stroke and SE in patients with non-valvular AF. Therefore, while the science reports included apixaban in addition to rivaroxaban and dabigatran, the recommendations presented in this report apply at present only to the two NOACs that are approved for this indication in Canada, namely dabigatran and rivaroxaban.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/867074010> # Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation
    a schema:CreativeWork, schema:MediaObject, schema:Book ;
    library:oclcnum "867074010" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    rdfs:seeAlso <http://experiment.worldcat.org/entity/work/data/2849314708#CreativeWork/anticoagulation_monitoring_and_reversal_strategies_for_dabigatran_rivaroxaban_and_apixaban_a_review_of_clinical_effectiveness> ; # Anticoagulation monitoring and reversal strategies for Dabigatran, Rivaroxaban, and Apixaban : a review of clinical effectiveness.
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/warfarin_therapeutic_use> ; # Warfarin--Therapeutic use
    schema:about <http://dewey.info/class/615.718/e23/> ;
    schema:about <http://id.worldcat.org/fast/1170802> ; # Warfarin--Therapeutic use
    schema:about <http://id.worldcat.org/fast/810470> ; # Anticoagulants (Medicine)--Therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/stroke_prevention_&_control> ; # Stroke--prevention & control
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/atrial_fibrillation_economics> ; # Atrial Fibrillation--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/anticoagulants_medicine_therapeutic_use> ; # Anticoagulants (Medicine)--Therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/anticoagulants_therapeutic_use> ; # Anticoagulants--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/2849314708#Topic/atrial_fibrillation_complications> ; # Atrial Fibrillation--complications
    schema:alternateName "New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation" ;
    schema:author <http://experiment.worldcat.org/entity/work/data/2849314708#Person/wells_george_a> ; # George A. Wells
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health.
    schema:datePublished "2012" ;
    schema:description "1. Executive summary: 1.1. Background; 1.2. Primary research questions; 1.3. Methods; 1.4. Results; 1.5. Strengths of review; 1.6. Limitations of review; 1.7. Conclusions -- 2. Introduction: 2.1. Background -- atrial fibrillation and anticoagulants; 2.2. Impact of the condition on the health of the population; 2.3. Interventions currently available; 2.4. New proposed treatments; 2.5. Possible benefits and safety of the old and new drugs; 2.6. Economic context -- 3. Clinical review: 3.1. Primary research questions; 3.2. Methods; 3.3. Systematic review results; 3.4. Individual study results; 3.5. Network meta-analysis results -- 4. Economic review: 4.1. Primary research questions; 4.2. Methods; 4.3. Results: sensitivity analysis; 4.4. Analysis of variability; 4.5. Analysis of the effect of changes in the duration of treatment effect -- 5. Discussion: 5.1. Summary of available evidence; 5.2. Interpretation of results; 5.3. Knowledge gaps; 5.4. Strengths and limitations -- 6. Conclusions -- 7. Appendices -- 8. References."@en ;
    schema:description "Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated with substantial morbidity. AF-related mortality is mainly attributable to complications of stroke. Stroke risk can be quantified using a validated tool such as the CHADS2 score. Warfarin, a vitamin K antagonist, is the standard of care for patients with AF and has demonstrated efficacy in the prevention of stroke. Warfarin has a narrow therapeutic window, produces varied responses among patients, and interacts with some types of food and other drugs, all of which necessitates routine laboratory monitoring. Improved understanding of the blood clotting cascade has led to the development of several new oral anticoagulants (NOACs) that offer a more targeted mechanism of anticoagulation. These NOACs include the direct thrombin inhibitor, dabigatran, and the direct factor Xa inhibitors, rivaroxaban and apixaban, which have either been approved (dabigatran and rivaroxaban) for use or are currently under regulatory review (apixaban) for the prevention of stroke and systemic embolism (SE) in patients with AF. Although NOACs have demonstrated efficacy within clinical trials in preventing stroke and SE in patients with AF, the relative effectiveness and cost-effectiveness in clinical practice of these agents is not clear. In addition, the relative effectiveness and cost-effectiveness of the NOACs and warfarin within specific subpopulations of AF patients is not clear. Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. Are there sub-populations of AF patients that would benefit more from using NOACs compared to warfarin?2. Are there sub-populations of AF patients that would benefit more from one of the NOACs versus another? At the time of this report, apixaban was not approved by Health Canada for the prevention of stroke and SE in patients with non-valvular AF. Therefore, while the science reports included apixaban in addition to rivaroxaban and dabigatran, the recommendations presented in this report apply at present only to the two NOACs that are approved for this indication in Canada, namely dabigatran and rivaroxaban."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/2849314708> ;
    schema:genre "Electronic books"@en ;
    schema:genre "Government publication"@en ;
    schema:genre "National government publication"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2849314708#Series/therapeutic_review> ; # Therapeutic review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2849314708#Series/cadth_therapeutic_review> ; # CADTH therapeutic review.
    schema:name "Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation"@en ;
    schema:productID "867074010" ;
    schema:url <http://www.deslibris.ca/ID/234905> ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK169793/> ;
    schema:url <http://site.ebrary.com/id/10617130> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/867074010> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2849314708#CreativeWork/anticoagulation_monitoring_and_reversal_strategies_for_dabigatran_rivaroxaban_and_apixaban_a_review_of_clinical_effectiveness> # Anticoagulation monitoring and reversal strategies for Dabigatran, Rivaroxaban, and Apixaban : a review of clinical effectiveness.
    a schema:CreativeWork ;
    schema:creator <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health.
    schema:name "Anticoagulation monitoring and reversal strategies for Dabigatran, Rivaroxaban, and Apixaban : a review of clinical effectiveness." ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Person/wells_george_a> # George A. Wells
    a schema:Person ;
    schema:familyName "Wells" ;
    schema:givenName "George A." ;
    schema:name "George A. Wells" ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Series/cadth_therapeutic_review> # CADTH therapeutic review.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/867074010> ; # Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation
    schema:name "CADTH therapeutic review." ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Series/therapeutic_review> # Therapeutic review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/867074010> ; # Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation
    schema:name "Therapeutic review" ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/anticoagulants_medicine_therapeutic_use> # Anticoagulants (Medicine)--Therapeutic use
    a schema:Intangible ;
    schema:name "Anticoagulants (Medicine)--Therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/anticoagulants_therapeutic_use> # Anticoagulants--therapeutic use
    a schema:Intangible ;
    schema:name "Anticoagulants--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/atrial_fibrillation_complications> # Atrial Fibrillation--complications
    a schema:Intangible ;
    schema:name "Atrial Fibrillation--complications"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/atrial_fibrillation_economics> # Atrial Fibrillation--economics
    a schema:Intangible ;
    schema:name "Atrial Fibrillation--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/stroke_prevention_&_control> # Stroke--prevention & control
    a schema:Intangible ;
    schema:name "Stroke--prevention & control"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2849314708#Topic/warfarin_therapeutic_use> # Warfarin--Therapeutic use
    a schema:Intangible ;
    schema:name "Warfarin--Therapeutic use"@en ;
    .

<http://id.worldcat.org/fast/1170802> # Warfarin--Therapeutic use
    a schema:Intangible ;
    schema:name "Warfarin--Therapeutic use"@en ;
    .

<http://id.worldcat.org/fast/810470> # Anticoagulants (Medicine)--Therapeutic use
    a schema:Intangible ;
    schema:name "Anticoagulants (Medicine)--Therapeutic use"@en ;
    .

<http://viaf.org/viaf/145374402> # Canadian Agency for Drugs and Technologies in Health.
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health." ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://www.worldcat.org/title/-/oclc/867074010>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/867074010> ; # Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing storke and other cardiovascular events in patients with atrial fibrillation
    schema:dateModified "2017-09-18" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.